首页> 外文OA文献 >Cutting edge: anti-CD154 therapeutic antibodies induce infectious transplantation tolerance.
【2h】

Cutting edge: anti-CD154 therapeutic antibodies induce infectious transplantation tolerance.

机译:前沿:抗CD154治疗性抗体可诱导感染性移植耐受。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Nondepleting anti-CD154 (CD40 ligand) mAbs have proven effective in inducing transplantation tolerance in rodents and primates. In the induction phase, anti-CD154 Ab therapy is known to enhance apoptosis of Ag reactive T cells. However, this may not be the sole explanation for tolerance, as we show in this study that tolerance is maintained through a dominant regulatory mechanism which, like tolerance induced with CD4 Abs, manifests as infectious tolerance. Therefore, tolerance induced with anti-CD154 Abs involves not only the deletion of potentially aggressive T cells, but also a contagious spread of tolerance to new cohorts of graft-reactive T cells as they arise.
机译:已证明非消耗性抗CD154(CD40配体)mAb可有效诱导啮齿动物和灵长类动物的移植耐受性。在诱导阶段,已知抗CD154 Ab治疗可增强Ag反应性T细胞的凋亡。但是,这可能不是耐受性的唯一解释,因为我们在这项研究中表明,耐受性是通过一种主要的调节机制得以维持的,该机制与CD4 Abs诱导的耐受性一样,表现为感染性耐受。因此,用抗CD154抗体诱导的耐受性不仅涉及潜在的侵袭性T细胞的缺失,而且还包括对新出现的移植物反应性T细胞群体的耐受性的传染性传播。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号